Pyrotinib dimaleate
CAT:
804-HY-104065B-02
Size:
5 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Pyrotinib dimaleate
- CAS Number: 1397922-61-0
- UNSPSC Description: Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively[1].
- Target Antigen: EGFR
- Type: Reference compound
- Related Pathways: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
- Applications: Cancer-Kinase/protease
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/Pyrotinib_dimaleate.html
- Purity: 98.56
- Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : ≥ 106 mg/mL
- Smiles: O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5.O=C(O)/C=C\C(O)=O.O=C(O)/C=C\C(O)=O
- Molecular Weight: 815.22
- References & Citations: [1]Li X, et al. Discovery and development of Pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017 Jan 21. pii: S0928-0987(17)30043-X.Int J Cancer. 2024 Jul 15;155(2):324-338.|Open Life Sci. 2023, 18(1).|Biomed Pharmacother. 2024 Oct 14:180:117523.|Biosci Rep. 2020 Feb 28;40(2):BSR20194167.|Cell Rep Med. 2023 Jan 10;100911.|Clin Transl Oncol. 2024 May 25.|Int J Biol Macromol. 2023 May 19;242(Pt 2):124870.|iScience. 2024 Jan 9;27(2):108839.|J Med Chem. 2019 May 9;62(9):4772-4778.|J Thorac Oncol. 2023 Sep 5;S1556-0864(23)00802-X.|Lung Cancer. 2018 Dec;126:72-79.|Mol Syst Biol. 2023 Dec 18.|Patent. US 20220175778A1.|Patent. US20210361655A1.|STAR Protoc. 2024 Apr 16;5(2):102987.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
- Clinical Information: Launched